Solid Biosciences said 40 participants have been dosed with SGT-003 in its Phase 1/2 INSPIRE DUCHENNE trial as of March 11, 2026. In muscle biopsies, mean microdystrophin expression was 60% by western blot at Day 90 (n=19) and 91% at Day 360 (n=3). Mean microdystrophin expression was 52% by mass spectroscopy at Day 90 (n=17) and 86% at Day 360. At Day 90, Solid reported mean reductions of 38% in serum creatine kinase and 43% in alanine transaminase. At Day 360, mean reductions were 37% in serum creatine kinase and 32% in aspartate aminotransferase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.